Genetic evidence for the effects of glucokinase activation on frailty‐related outcomes: A Mendelian randomisation study
Our study provides genetic evidence supporting the causal effects of GK activation on lowering the risk of frailty. These findings suggest that GK activators (GKAs) may aid in the management of frailty and sarcopaenia in people with diabetes; however, future randomized controlled trials are necessary to validate these results and establish their clinical applicability.
Authors
- Aimin Yang (ORCID: https://orcid.org/0000-0003-2968-1762)
- Mai Shi (ORCID: https://orcid.org/0000-0002-2798-3268)
- Elaine Chow (ORCID: https://orcid.org/0000-0002-4147-3387)
- Yin Ting Cheung (ORCID: https://orcid.org/0000-0001-9874-8938)
- Rong Hua (ORCID: https://orcid.org/0000-0002-0006-9441)
Institutions
- Chinese University of Hong Kong (HK)
- Prince of Wales Hospital (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1111/dom.16312
- Citations
- 1
- Primary Topic
- Frailty in Older Adults
- Type
- article
- Field-Weighted Citation Impact
- 1.22